8-K: Genprex Faces Nasdaq Delisting, Announces 1:50 Reverse Split

Genprex, Inc. received a Nasdaq extension for listing compliance until October 31, 2025, and will implement a 1:50 reverse stock split to address bid price deficiencies, while also providing updates on its oncology and diabetes gene therapy programs.

Summary

• Nasdaq granted Genprex an exception until October 31, 2025, to regain compliance with the $1.00 minimum bid price and $2.5 million minimum stockholders' equity requirements.
• The Nasdaq Panel has discretion to extend this exception until February 9, 2026.
• A one-for-fifty (1:50) reverse stock split will become effective at 12:01 a.m. Eastern Time on October 21, 2025, with trading on a split-adjusted basis commencing the same day.
• The reverse stock split aims to help regain compliance with the Nasdaq minimum bid price requirement.
• In oncology, the Acclaim-1 (NSCLC) and Acclaim-3 (ES-SCLC) Phase 2a/2 expansion portions are enrolling patients, with interim analyses expected in the second half of 2026.
• New clinical trial sites for Acclaim-1 and Acclaim-3 are being added and are expected to open by the end of 2025 to expedite patient enrollment.
• The diabetes gene therapy program (GPX-002) is in preclinical studies, with plans to submit a request to the FDA for a meeting regarding IND-enabling studies by the end of 2025.

Sentiment

Score: 3

Explanation: While the company received an extension from Nasdaq and is taking steps to regain compliance, the necessity of a 1:50 reverse stock split and the ongoing non-compliance with equity requirements indicate significant financial challenges. The clinical trial updates are positive but represent expected progress rather than unexpected breakthroughs, and the diabetes program has seen a delay in regulatory discussions. The overall sentiment is cautious due to the immediate financial and listing pressures.

Positives

• Nasdaq granted an exception for continued listing through October 31, 2025, with potential for extension to February 9, 2026.
• Acclaim-1 and Acclaim-3 clinical trials have received FDA Fast Track Designation.
• Acclaim-3 clinical trial has also received FDA Orphan Drug Designation.
• Addition of new clinical trial sites for Acclaim-1 and Acclaim-3 is expected to expedite patient enrollment.
• Collaboration with MD Anderson Cancer Center for biomarker research could further expedite patient enrollment.

Negatives

• The company is currently non-compliant with Nasdaq's $1.00 minimum bid price and $2.5 million minimum stockholders' equity requirements.
• The reverse stock split may not proportionally increase the stock price and could negatively affect liquidity and market capitalization.
• There is no assurance that the Nasdaq Panel will grant an extension beyond October 31, 2025, or that the company will regain and maintain compliance.
• Delisting from Nasdaq could severely impact stock liquidity, price, and ability to raise capital.

Risks

• Failure to regain and maintain compliance with Nasdaq's continued listing requirements could lead to delisting.
• Delisting could negatively impact the common stock price and the company's ability to access capital markets.
• The announcement and implementation of the reverse stock split could negatively affect the price of common stock.
• Prices for shares after the reverse stock split may not increase proportionately or be maintained for any period.
• Liquidity may be adversely affected by the reduced number of shares outstanding after the reverse stock split.
• Total market capitalization after the reverse stock split may be lower than before.
• Raising additional capital through equity issuance could result in dilution and negatively affect the price of securities.
• The Nasdaq Panel reserves the right to reconsider the exception based on any adverse event, condition, or circumstance.

Future Outlook

Genprex anticipates completing enrollment for interim analyses in its Acclaim-1 and Acclaim-3 oncology trials in the first half of 2026, with interim results expected in the second half of 2026. The company plans to open additional clinical trial sites by the end of 2025 to accelerate enrollment. For its diabetes gene therapy program, Genprex expects to submit a request to the FDA for a meeting regarding IND-enabling studies by the end of 2025. The company intends to take definitive steps, including the reverse stock split, to regain and maintain compliance with Nasdaq listing requirements, though there is no assurance of success or further extensions.

Management Comments

• We fully intend to provide the Panel with prompt notification of any significant events that occur, including any event that may call into question our ability to satisfy the terms of the Exception.
• We intend to continue to take definitive steps in an effort to evidence compliance with the Bid Price Requirement and the Minimum Stockholders Equity Requirement and the other Nasdaq listing requirements, including by the implementation of the one-for-fifty (1:50) reverse stock split.
• We believe the addition of new sites will expedite patient enrollment in both Acclaim-1 and Acclaim-3.
• We believe [biomarker research] could expedite patient enrollment.

Industry Context

The biotechnology and pharmaceutical industry is highly competitive and capital-intensive, with significant regulatory hurdles. Companies like Genprex, focused on gene therapies for oncology and diabetes, often face prolonged development timelines and substantial R&D costs. Maintaining Nasdaq listing is crucial for access to capital and investor visibility, especially for clinical-stage companies. Reverse stock splits are a common tactic to meet minimum bid price requirements, but their long-term effectiveness in boosting investor confidence and stock value is often debated. The FDA Fast Track and Orphan Drug designations for its oncology programs indicate potential for expedited review, which is a positive signal in the drug development landscape.

Corporate Governance

Stakeholder Impact

• Shareholders: Will experience a 1:50 reverse stock split, potentially impacting stock price and liquidity. Risk of dilution if new capital is raised. Risk of delisting could significantly reduce investment value.
• Employees: Delisting could impact company morale and ability to attract/retain talent due to reduced stock value and market visibility.
• Investors/Analysts: The filing provides critical updates on Nasdaq listing status, clinical pipeline progress, and future strategic plans, essential for investment decisions.
• Regulatory Authorities (FDA): Ongoing interactions regarding Fast Track and Orphan Drug designations, and future IND-enabling studies for diabetes program.
• Partners (AstraZeneca, Genentech, University of Pittsburgh, MD Anderson Cancer Center): Continued collaboration on clinical trials and research.

Next Steps

• Provide prompt notification to the Nasdaq Panel of any significant events.
• Request a further extension from Nasdaq beyond October 31, 2025, if needed.
• Common stock to begin trading on a Reverse Stock Split-adjusted basis on October 21, 2025.
• Continue to take definitive steps to evidence compliance with Nasdaq listing requirements.
• Complete enrollment of the first 19 patients for interim analysis in Acclaim-1 Phase 2a in the first half of 2026.
• Complete enrollment of the first 25 patients for interim analysis in Acclaim-3 Phase 2 in the first half of 2026.
• Conduct interim analysis for Acclaim-1 and Acclaim-3 studies in the second half of 2026.
• Open additional clinical trial sites for Acclaim-1 and Acclaim-3 by the end of 2025.
• Continue biomarker research with MD Anderson Cancer Center.
• Initiate research in Type 2 diabetes animal models.
• Submit a request to the FDA to meet regarding IND-enabling studies for diabetes gene therapy by the end of 2025.
• Monitor stockholders' equity and consider options, including raising additional capital.

Key Dates

Recommendation

The company is at a critical juncture, addressing immediate Nasdaq listing compliance issues with a reverse stock split and an extension. While the extension provides a temporary reprieve and the clinical programs show progress with FDA designations, the underlying financial weakness (low stockholders' equity) and the inherent risks of a reverse stock split (potential for further price decline, reduced liquidity) create significant uncertainty. The diabetes program's regulatory delay adds to the cautious outlook. An investor should hold to observe if the company successfully regains and maintains Nasdaq compliance and if the clinical pipeline progresses positively without further significant capital raises that would cause substantial dilution. A 'buy' would be premature given the risks, and a 'sell' might be an overreaction if the company successfully navigates the listing challenges and clinical milestones.

Keywords

Genprex, GNPX, Nasdaq, Delisting, Reverse Stock Split, Clinical Trials, Oncology, Diabetes Gene Therapy, REQORSA, Tagrisso, Tecentriq, NSCLC, ES-SCLC, FDA Fast Track, Orphan Drug Designation, Biotechnology, Pharmaceuticals